Hepatitishäufigkeit, HBs-Antigen- und Anti-HBs-Frequenz bei Patienten des Hämodialysezentrums Heidelberg

Schimpf, Kl.; Zimmermann, Kathrin; Thamer, G; Rüdel, J.

doi:10.1007/978-3-642-85451-4_93

Cited by 4 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While these concentrates revolutionized the treatment of haemophilia, they required the pooling of large quantities of human fresh‐frozen plasma preparations, and it soon became evident that non‐treated concentrates carried a considerable risk of transmitting viral diseases. In the mid 1970s, a growing number of reports of icteric hepatitis in patients receiving plasma concentrates for haemophilia began to appear [8–13]. Unexpectedly, post‐transfusion hepatitis rates of 60% and chronic liver disease had become major problems in patients receiving factor concentrates.…”

Section: Introductionmentioning

confidence: 99%

Haemate^®P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience

Schramm¹

2008

Haemophilia

View full text Add to dashboard Cite

Although von Willebrand disease (VWD) has a very long history, our understanding and treatment of the bleeding disorder has only evolved during the past 50 years or so. It was not until the 1920s that VWD was first recognized as a disease separate from that of classical haemophilia. It then took another 30 years before the first effective treatment was developed. Since then, the medical management of VWD has evolved considerably, but not without its ups and downs. One of the key milestones in the evolution of the treatment of VWD was the development of Haemate P/Humate-P (CSL Behring) - the first virus-inactivated factor VIII plasma product. For 25 years, this concentrate has demonstrated excellent clinical efficacy and safety for patients with VWD and for those with haemophilia. This article provides an historical overview of the early landmark efforts to ensure a safe plasma-derived replacement product and outlines the clinical evolution in the use of Haemate P.

show abstract

Section: Introductionmentioning

confidence: 99%

Haemate^®P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience

Schramm¹

2008

Haemophilia

View full text Add to dashboard Cite

show abstract

Hämophilie

Lechner¹

1985

Blut Und Blutkrankheiten

View full text Add to dashboard Cite

Die Bedeutung der kontrollierten Selbstbehandlung f�r den H�mophiliepatienten

Schimpf

1978

Blut

View full text Add to dashboard Cite

Hepatitishäufigkeit, HBs-Antigen- und Anti-HBs-Frequenz bei Patienten des Hämodialysezentrums Heidelberg

Cited by 4 publications

References 1 publication

Haemate^®P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience

Haemate^®P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience

Hämophilie

Die Bedeutung der kontrollierten Selbstbehandlung f�r den H�mophiliepatienten

Contact Info

Product

Resources

About

Hepatitishäufigkeit, HBs-Antigen- und Anti-HBs-Frequenz bei Patienten des Hämodialysezentrums Heidelberg

Cited by 4 publications

References 1 publication

Haemate®P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience

Haemate®P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience

Hämophilie

Die Bedeutung der kontrollierten Selbstbehandlung f�r den H�mophiliepatienten

Contact Info

Product

Resources

About

Haemate^®P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience

Haemate^®P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience